195 related articles for article (PubMed ID: 26341985)
1. Potassium channels in pulmonary arterial hypertension.
Boucherat O; Chabot S; Antigny F; Perros F; Provencher S; Bonnet S
Eur Respir J; 2015 Oct; 46(4):1167-77. PubMed ID: 26341985
[TBL] [Abstract][Full Text] [Related]
2. Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.
Le Ribeuz H; Capuano V; Girerd B; Humbert M; Montani D; Antigny F
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32882918
[TBL] [Abstract][Full Text] [Related]
3. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
[TBL] [Abstract][Full Text] [Related]
4. The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.
Hayabuchi Y
Pediatr Cardiol; 2017 Jan; 38(1):1-14. PubMed ID: 27826710
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Heterozygous
Bohnen MS; Roman-Campos D; Terrenoire C; Jnani J; Sampson KJ; Chung WK; Kass RS
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28889099
[TBL] [Abstract][Full Text] [Related]
6. Novel Loss-of-Function
Vera-Zambrano A; Lago-Docampo M; Gallego N; Franco-Gonzalez JF; Morales-Cano D; Cruz-Utrilla A; Villegas-Esguevillas M; Fernández-Malavé E; Escribano-Subías P; Tenorio-Castaño JA; Perez-Vizcaino F; Valverde D; González T; ; Cogolludo A
Am J Respir Cell Mol Biol; 2023 Aug; 69(2):147-158. PubMed ID: 36917789
[TBL] [Abstract][Full Text] [Related]
7. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries.
Mondejar-Parreño G; Callejo M; Barreira B; Morales-Cano D; Esquivel-Ruiz S; Moreno L; Cogolludo A; Perez-Vizcaino F
J Physiol; 2019 Feb; 597(4):1185-1197. PubMed ID: 29717493
[TBL] [Abstract][Full Text] [Related]
8. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.
Remillard CV; Tigno DD; Platoshyn O; Burg ED; Brevnova EE; Conger D; Nicholson A; Rana BK; Channick RN; Rubin LJ; O'connor DT; Yuan JX
Am J Physiol Cell Physiol; 2007 May; 292(5):C1837-53. PubMed ID: 17267549
[TBL] [Abstract][Full Text] [Related]
9. In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression.
Le Ribeuz H; Courboulin A; Ghigna MR; Lambert M; Hautefort A; Humbert M; Montani D; Cohen-Kaminsky S; Perros F; Antigny F
Respir Res; 2020 Jul; 21(1):186. PubMed ID: 32678044
[TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular pathobiology of pulmonary arterial hypertension.
Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174
[TBL] [Abstract][Full Text] [Related]
11. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation.
Seyler C; Duthil-Straub E; Zitron E; Gierten J; Scholz EP; Fink RH; Karle CA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2012 Mar; 165(5):1467-75. PubMed ID: 21838752
[TBL] [Abstract][Full Text] [Related]
12. KCNK3: new gene target for pulmonary hypertension?
Girerd B; Perros F; Antigny F; Humbert M; Montani D
Expert Rev Respir Med; 2014 Aug; 8(4):385-7. PubMed ID: 24742047
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
Dumas de la Roque E; Savineau JP; Bonnet S
Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of NOX1/nicotinamide adenine dinucleotide phosphate, reduced form oxidase leads to pulmonary vascular remodeling.
Iwata K; Ikami K; Matsuno K; Yamashita T; Shiba D; Ibi M; Matsumoto M; Katsuyama M; Cui W; Zhang J; Zhu K; Takei N; Kokai Y; Ohneda O; Yokoyama T; Yabe-Nishimura C
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):110-9. PubMed ID: 24233492
[TBL] [Abstract][Full Text] [Related]
15. Characterization of
Lambert M; Capuano V; Boet A; Tesson L; Bertero T; Nakhleh MK; Remy S; Anegon I; Pechoux C; Hautefort A; Rucker-Martin C; Manoury B; Domergue V; Mercier O; Girerd B; Montani D; Perros F; Humbert M; Antigny F
Circ Res; 2019 Sep; 125(7):678-695. PubMed ID: 31347976
[TBL] [Abstract][Full Text] [Related]
16. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
Guignabert C; Tu L; Girerd B; Ricard N; Huertas A; Montani D; Humbert M
Chest; 2015 Feb; 147(2):529-537. PubMed ID: 25644906
[TBL] [Abstract][Full Text] [Related]
17. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.
Cunningham KP; Holden RG; Escribano-Subias PM; Cogolludo A; Veale EL; Mathie A
J Physiol; 2019 Feb; 597(4):1087-1101. PubMed ID: 30365877
[TBL] [Abstract][Full Text] [Related]
18. Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension.
Redel-Traub G; Sampson KJ; Kass RS; Bohnen MS
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291551
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells.
Le Ribeuz H; Dumont F; Ruellou G; Lambert M; Balliau T; Quatredeniers M; Girerd B; Cohen-Kaminsky S; Mercier O; Yen-Nicolaÿ S; Humbert M; Montani D; Capuano V; Antigny F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036472
[TBL] [Abstract][Full Text] [Related]
20. Ion channels in pulmonary arterial hypertension.
Mandegar M; Remillard CV; Yuan JX
Prog Cardiovasc Dis; 2002; 45(2):81-114. PubMed ID: 12411972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
